Affimed

Affimed company information, Employees & Contact Information

Explore related pages

Related company profiles:

Affimed N.V. (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s Innate Cell Engagers (ICE®), generated from its proprietary ROCK® platform, are bispecific antibodies, which target innate immune cells, e.g. natural killer (NK) cells and macrophages, to destroy tumor cells. Affimed’s ICE® enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors with activity demonstrated as monotherapy and when given in combination with NK cells and other I-O therapeutics. Affimed has three active clinical programs focused on solid tumors and blood cancers. The lead candidate Acimtamig (AFM13) is in development for patients with CD30-positive lymphomas. Acimtamig combined with NK cells has demonstrated high objective response rates in heavily pretreated, relapsed / refractory (r/r) Hodkin lymphoma (HL) patients with a manageable safety profile in a clinical trial (AFM13-104). Affimed’s phase 2 study, LuminICE-203, is underway to investigate acimtamig in combination with AlloNK® (also known as AB-101), an off-the-shelf, allogeneic NK cell from Artiva Biotherapeutics, in patients with r/r HL with an exploratory arm planned in patients with r/r/ peripheral T-cell lymphoma (PTCL). AFM24 is in development for epidermal growth factor receptor (EGFR)-expressing solid tumors. Based on the data generated to date, the developmental focus of AFM24 is in combination with the anti-PD-L1 inhibitor atezolizumab in advanced stage EGFR-positive non-small cell lung cancer (NSCLC). AFM28 is being developed for patients with CD123-expressing acute myeloid leukemia (AML) in need of new therapeutic options. A first-in-human Phase 1 clinical study is underway (AFM28-101) and development in combination with allogeneic NK cell therapy is being explored.

Company Details

Employees
76
Founded
-
Address
Gottlieb-Daimler Straße 2, Mannheim,bw 68165,germany
Phone
+49 (0)6221-6743-60
Email
in****@****med.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
jobs.
HQ
Mannheim, BW
Looking for a particular Affimed employee's phone or email?

Affimed Questions

News

Affimed Announces Filing for the Opening of Insolvency Proceedings - GlobeNewswire

Affimed Announces Filing for the Opening of Insolvency Proceedings GlobeNewswire

Affimed Announces Filing for the Opening of Insolvency Proceedings - Stock Titan

Affimed Announces Filing for the Opening of Insolvency Proceedings Stock Titan

Affimed Announces Receipt of Nasdaq Delisting Notice - Yahoo! Finance UK

Affimed Announces Receipt of Nasdaq Delisting Notice Yahoo! Finance UK

Higher AFM24 Exposure Boosts Response in Advanced NSCLC: AACR Data - Targeted Oncology

Higher AFM24 Exposure Boosts Response in Advanced NSCLC: AACR Data Targeted Oncology

Acimtamig Plus AlloNK Elicits Responses in Heavily Pretreated R/R Hodgkin Lymphoma - OncLive

Acimtamig Plus AlloNK Elicits Responses in Heavily Pretreated R/R Hodgkin Lymphoma OncLive

Affimed needs more time with AFM24 | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Affimed needs more time with AFM24 | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement - Yahoo! Finance UK

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement Yahoo! Finance UK

Affimed Stock to Be Delisted from Nasdaq, Trading Suspended May 20 Following Insolvency - Stock Titan

Affimed Stock to Be Delisted from Nasdaq, Trading Suspended May 20 Following Insolvency Stock Titan

Affimed N.V. Announces Accepted Abstracts for Oral and Poster Presentations at ASCO 2025 Annual Meeting - Nasdaq

Affimed N.V. Announces Accepted Abstracts for Oral and Poster Presentations at ASCO 2025 Annual Meeting Nasdaq

Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts - Seeking Alpha

Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts Seeking Alpha

ASCO 2024 movers – Affimed wins, Caribou loses | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASCO 2024 movers – Affimed wins, Caribou loses | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better! (NASDAQ:AFMD) - Seeking Alpha

Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better! (NASDAQ:AFMD) Seeking Alpha

Affimed Announces Leadership Change and Organizational Restructuring - Yahoo Finance

Affimed Announces Leadership Change and Organizational Restructuring Yahoo Finance

ASH 2024 – Affimed plays up AFM28's safety, despite one death | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASH 2024 – Affimed plays up AFM28's safety, despite one death | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Affimed and Roivant Sciences Announce Licensing and - GlobeNewswire

Affimed and Roivant Sciences Announce Licensing and GlobeNewswire

Affimed Announces Clinical Updates at the Annual Meeting of the American Association for Cancer Research - GlobeNewswire

Affimed Announces Clinical Updates at the Annual Meeting of the American Association for Cancer Research GlobeNewswire

Is Affimed N.V. (AFMD) the Best German Stock to Buy Now? - Yahoo Finance

Is Affimed N.V. (AFMD) the Best German Stock to Buy Now? Yahoo Finance

Affimed tries to convince with seven patients | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Affimed tries to convince with seven patients | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

AFM24 Plus Atezolizumab Wins FDA Fast Track Designation for EGFR Wild-Type NSCLC - OncLive

AFM24 Plus Atezolizumab Wins FDA Fast Track Designation for EGFR Wild-Type NSCLC OncLive

Affimed looks to reverse a share price collapse | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Affimed looks to reverse a share price collapse | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

FDA grants RMAT to Affimed and Artiva’s lymphoma therapy - Pharmaceutical Technology

FDA grants RMAT to Affimed and Artiva’s lymphoma therapy Pharmaceutical Technology

Affimed’s natural killer cell therapy has murky path forward despite encouraging results - statnews.com

Affimed’s natural killer cell therapy has murky path forward despite encouraging results statnews.com

683 Capital Management, LLC Expands Stake in Affimed NV - Yahoo Finance

683 Capital Management, LLC Expands Stake in Affimed NV Yahoo Finance

Cantor Fitzgerald cuts Affimed stock rating on insolvency news - Investing.com

Cantor Fitzgerald cuts Affimed stock rating on insolvency news Investing.com

With no-go from FDA, Affimed looks elsewhere for its AML bispecific's first human study - Fierce Biotech

With no-go from FDA, Affimed looks elsewhere for its AML bispecific's first human study Fierce Biotech

Affimed Collaborates with Genentech in Cancer Immunotherapy Deal Worth €4.4B - Labiotech.eu

Affimed Collaborates with Genentech in Cancer Immunotherapy Deal Worth €4.4B Labiotech.eu

CEO exit, staff layoffs as Affimed grapples with setback - FirstWord Pharma

CEO exit, staff layoffs as Affimed grapples with setback FirstWord Pharma

Immuno-oncology company Affimed to be delisted from Nasdaq after insolvency filing (AFMD:NASDAQ) - Seeking Alpha

Immuno-oncology company Affimed to be delisted from Nasdaq after insolvency filing (AFMD:NASDAQ) Seeking Alpha

MD Anderson and Affimed announce clinical immuno-oncology development collaboration - MD Anderson Cancer Center

MD Anderson and Affimed announce clinical immuno-oncology development collaboration MD Anderson Cancer Center

Affimed Files for Insolvency Amid Financial Challenges - TipRanks

Affimed Files for Insolvency Amid Financial Challenges TipRanks

Affimed NV - The Pharma Letter

Affimed NV The Pharma Letter

Affimed stock falls as finance and science heads exit - Seeking Alpha

Affimed stock falls as finance and science heads exit Seeking Alpha

Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method - Taylor & Francis Online

Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method Taylor & Francis Online

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors - Taylor & Francis Online

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors Taylor & Francis Online

Full article: Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method - Taylor & Francis Online

Full article: Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method Taylor & Francis Online

Affimed tumbles as it puts brakes on T cell engager - Fierce Biotech

Affimed tumbles as it puts brakes on T cell engager Fierce Biotech

Affimed Receives Nasdaq Deficiency Notice Over Low Share Price: Retail’s In Wait-And-Wait Mode - Stocktwits

Affimed Receives Nasdaq Deficiency Notice Over Low Share Price: Retail’s In Wait-And-Wait Mode Stocktwits

Affimed lands big, backloaded immunotherapy deal with Genentech, sending its stock into overdrive - Fierce Biotech

Affimed lands big, backloaded immunotherapy deal with Genentech, sending its stock into overdrive Fierce Biotech

Affimed Joins Forces with Roivant in Fight Against Cancer - BioSpace

Affimed Joins Forces with Roivant in Fight Against Cancer BioSpace

Frontrunners in Bispecific Antibodies - PharmTech

Frontrunners in Bispecific Antibodies PharmTech

AFMD - Affimed Latest Stock News & Market Updates - Stock Titan

AFMD - Affimed Latest Stock News & Market Updates Stock Titan

Roche and Affimed in US$5bn cancer deal - European Biotechnology Magazine

Roche and Affimed in US$5bn cancer deal European Biotechnology Magazine

Genentech, Affimed Launch Up-to-$5B Cancer Immunotherapy Collaboration - Genetic Engineering and Biotechnology News

Genentech, Affimed Launch Up-to-$5B Cancer Immunotherapy Collaboration Genetic Engineering and Biotechnology News

Affimed halts trial after patient death and SAEs - European Biotechnology Magazine

Affimed halts trial after patient death and SAEs European Biotechnology Magazine

Affimed Places Cancer Immunotherapy Candidate AFM11 on Clinical Hold after Patient Death - Genetic Engineering and Biotechnology News

Affimed Places Cancer Immunotherapy Candidate AFM11 on Clinical Hold after Patient Death Genetic Engineering and Biotechnology News

Top Affimed Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant